Koselugo (Selumetinib)

Plexiform Neurofibromas

Class: Antineoplastic Agents

FDA approved for medical use in the United States in April 2020

Pill

Medscape. "FDA Approves Koselugo for Pediatric Neurofibromatosis Treatment." (2020) https://www.medscape.com/viewarticle/928598

Selumetinib was discovered by Array BioPharma and was licensed to AstraZeneca. It has been investigated for the treatment of various types of cancer, such as non-small cell lung cancer (NSCLC) and thyroid cancer.

koselugo (Selumetinib) Brand Koselugo INN (Selumetinib) kinase inhibitor Class: Antineoplastic Agents similar to chemotherapy Selumetinib was discovered by Array BioPharma and was licensed to AstraZeneca. It has been investigated for the treatment of various types of cancer, such as non-small cell lung cancer (NSCLC) and thyroid cancer. pill approved for medical use in the United States in April 2020 AZD6244, ARRY-142886, AZD6244, AZD 6244, ARRY-142886, Selumetinib, 606143-52-6, AZD6244, AZD 6244, ARRY-142886, AZD-6244, Selumetinib (AZD6244) 5-[(4-BROMO-2-CHLOROPHENYL)AMINO]-4-FLUORO-N-(2-HYDROXYETHOXY)-1-METHYL-1H-BENZIMIDAZOLE-6-CARBOXAMIDE CID: C17H15BrClFN4O3
poor prognosis: low chance of recovery